Apyx Medical Corporation (APYX) News
Follow Apyx Medical Corporation (APYX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Apyx Medical 3Q 2026: Revenue $14.03M, EPS ($0.04) — 10-Q Summary
Apyx Medical's third-quarter sales rose 9.0% year over year, while its net loss narrowed. Growth in Surgical Aesthetics, led by AYON sales and higher international generator sales, was partly offset by lower single-use h
EARNINGS | Nov 05, 2026, 04:03 PM UTC
M
Apyx Medical Reports Quarterly Results Through September 30
Apyx Medical reported results for the quarter ended September 30; the supplied report provides no financial figures.
EQUITY | Nov 05, 2026, 03:21 PM UTC
M
Apyx Medical Reports Third-Quarter 2026 Revenue of $14.0 Million
Apyx Medical reported third-quarter 2026 revenue of $14.0 million, driven by 17% growth in the Sur
EQUITY | Nov 05, 2026, 12:32 PM UTC
L
Apyx Medical publishes human histology data showing increased elastin, reduced inflammation after Renuvion
Apyx Medical announced a prospective study showing Renuvion treatment produced measurable increases in elastin and reduced inflammation at Day 180.Key Highlights:Original SEC Filing: Apyx Medical Corp [ APYX ] - 8-K - Se
REGULATION | Sep 29, 2026, 08:23 PM UTC
L
Apyx Medical Initiated at Buy by Maxim Group
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 04:46 PM UTC
L
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
Patients reported high satisfaction and visible improvements in skin elasticity, youthfulness, and radianceCLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation NASDAQ:APYX (“Apyx Medical” or the
NEWS | Sep 29, 2026, 12:09 PM UTC
L
APYX: Driving growth in surgical aesthetics with innovative, FDA-cleared solutions and global reach
APYX: Driving growth in surgical aesthetics with innovative, FDA-cleared solutions and global reach
REGULATION | Aug 28, 2026, 12:54 PM UTC
L
Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.554M Est
Apyx Medical (NASDAQ: APYX ) affirms FY2026 sales outlook from $59.000 million-$60.000 million to $59.000 million-$60.000 million vs $59.554 million estimate.
EARNINGS | Aug 06, 2026, 08:20 PM UTC